In addition to direct EPRS1 inhibitors, investigation into potential antagonists that block EPRS1 phosphorylation and dissociation from MSCs (e.g., kinase inhibitors) are interesting candidates for application to cancer therapy. This evidence concerns the gene EPRS1 and cancer.